Sure, I will keep you posted if i get a reply from them. Unfortunately, I am not living in the States, and its crazy expensive to call overseas.
I am not sure about the platforms from Amyris, Evolva, Noramco, and Dalton Pharma that you mentioned, but if they are based on mammalian cells, it is likely that the production volume will be very little as compared to C1. If it is based on non-mammalian cells, c1 is likely the human like non mammalian cell out there, so the competition is likely not too stiff i guess. This is what i gathered from asking the PhD and reading an old article.
"C1 produces glycan structures more similar to the human glycan forms than most other non-mammalian production hosts, making the glycoengineering work carried out in the project quicker and easier. Dyadic has developed and used its C1 production platform to produce industrial enzymes since the late 1990's."
News 
Market Data 
Discover 
